Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +47.56%
#3 Cysic Cysic +41.67%
#4 Glidr Glidr +36.41%
#5 Walrus Walrus +29.37%
#6 Humanity Humanity +23.38%
#7 Codatta Codatta +16.38%
#8 Enso Enso +16.32%
#9 Tutorial Tutorial +15.81%
#10 Ribbita by Virtuals Ribbita by Virtuals +14.43%
Coin of the day
EXOD EXOD
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Kedudukan dalam Saham #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Harga Saham
$0.6
Disegerakkan terakhir: 2024-08-14
Modal Pasaran
$2.09M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
SG
Perdagangan ASLAN Pharmaceuticals Limited (ASLN)

Kategori

Healthcare
Pendapatan untuk ASLAN Pharmaceuticals Limited (ASLN)
Pendapatan pada Mar 2024 TTM: $-34.90M
Menurut laporan kewangan terkini ASLAN Pharmaceuticals Limited, pendapatan semasa syarikat ialah $-34.90M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-51.28M, penurunan berbanding pendapatan pada tahun 2021 yang berjumlah $-31.59M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi ASLAN Pharmaceuticals Limited dari 2014 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-34.90M -20.84%
2023 $-44.09M -14.03%
2022 $-51.28M 62.34%
2021 $-31.59M 86.14%
2020 $-16.97M -63.63%
2019 $-46.66M 10.64%
2018 $-42.17M 3.58%
2017 $-40.71M 352.17%
2016 $-9.00M -32.43%
2015 $-13.33M 80.95%
2014 $-7.36M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -15,214.03%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -5,689.14%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -8,712.20%
BE